Chondrosarcoma is a malignant tumor characterized by the formation of cartilage. A case of primary cardiac chondrosarcoma of the left atrium developed in a middle-aged male. The preoperative serum concentrations of C-parathyroid hormone-related protein (PTHrP) and calcium were high (413.2 pmol/L and 12.2 mg/dl, respectively), but normalized after resection of the tumor, which measured 7 x 5 x 3.5 cm. The tumor was histopathologically diagnosed as chondrosarcoma, composed of outer atypical chondroid cells and inner pleomorphic and spindle mesenchymal cells mimicking malignant fibrous histiocytoma. Half of the cartilaginous tumor cells and a few pleomorphic cells showed cytoplasmic immunoreactivity for PTHrP. The tumor is a possible example of the functional pleiotropy of chondrosarcoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1253/circj.68.715 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sternal Reconstruction with a Custom-Made 3D-Printed Titanium Neo-sternum Prosthesis After Resection for Primary Malignant Sternal Tumour.
Indian J Surg Oncol
September 2024
Institute of Chest Surgery, Medanta, Room No. 8, Fourth Floor, Gurugram, India.
Primary sternal tumours are rare. Most of them are malignant in nature. When localized, cure can be achieved by radical resection.
View Article and Find Full Text PDFThe ketone body β-Hydroxybutyrate as a fuel source of chondrosarcoma cells.
Heliyon
May 2024
Laboratorio de Microbiología Molecular, Sección de Estudios de Posgrado e Investigación, ENMyH, Instituto Politécnico Nacional, Mexico City, 07320, Mexico.
Chondrosarcoma (CS) is a malignant bone tumor arising from cartilage-producing cells. The conventional subtype of CS typically develops within a dense cartilaginous matrix, creating an environment deficient in oxygen and nutrients, necessitating metabolic adaptation to ensure proliferation under stress conditions. Although ketone bodies (KBs) are oxidized by extrahepatic tissue cells such as the heart and brain, specific cancer cells, including CS cells, can undergo ketolysis.
View Article and Find Full Text PDFHigh Risk of Heart Tumors after COVID-19.
Life (Basel)
October 2023
Almazov National Medical Research Centre, 197341 St. Petersburg, Russia.
Unlabelled: An emergence of evidence suggests that severe COVID-19 is associated with an increased risk of developing breast and gastrointestinal cancers. The aim of this research was to assess the risk of heart tumors development in patients who have had COVID-19.
Methods: A comparative analysis of 173 heart tumors was conducted between 2016 and 2023.
18 F-FDG PET/CT Imaging Findings of a Case of Primary Cardiac Chondrosarcoma and Pulmonary Inflammation.
Clin Nucl Med
September 2023
From the Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences.
Primary cardiac chondrosarcoma invading the right pulmonary vein is very rare, whereas secondary cardiac chondrosarcoma is relatively common. We reported the 18 F-FDG PET/CT findings of primary cardiac chondrosarcoma and pulmonary inflammation misdiagnosed as cardiac malignancy and pulmonary metastasis in a 27-year-old man.
View Article and Find Full Text PDFPrimary pulmonary artery chondrosarcoma: case report.
Transl Cancer Res
April 2023
Department of Radiation Oncology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China.
Background: Primary pulmonary artery sarcoma (PAS) is a rare tumor that presents like pulmonary embolism (PE), primary chondrosarcoma in the pulmonary artery is even rarer and few studies have been reported. PAS are commonly misinterpreted as in a clinical setting, many patients initially receive anticoagulant and thrombolysis therapy, but failed to respond. Management of this condition is difficult and prognosis is poor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!